Search results
Showing 226 to 240 of 1254 results for criteria
Step 1 - the criteria Before you decide to apply, take a look through the supporting information to make sure you meet the...
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713
In development Reference number: GID-TA11952 Expected publication date: TBC
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.
Topical tapinarof for treating mild to severe plaque psoriasis ID6712
In development Reference number: GID-TA11951 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716
In development Reference number: GID-TA11925 Expected publication date: TBC
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.